중독성 질환으로서의 흡연
Smoking as an Addictive Disorder
0
조회
0
다운로드
3
인용
0
참고문헌
초록
Nicotine is the major substance that accounts for the addictive nature of smoking. Nicotine induces neurobiological and behavioral responses through diverse neurochemical mechanisms over the central nervous system. The brain reward system, particularly the dopaminergic pathway from the ventral tegmental area to nucleus accumbens, is central to understanding the behavioral reinforcement underlying substance addictions such as the addiction to nicotine. Nicotine acts as an agonist provoking activation or desensitization of nicotinic acetylcholine receptors in different brain areas including the brain reward system. Nicotine also indirectly influences the glutaminergic, GABAergic, noradrenergic, and serotonergic neurotransmission that lead ultimately to activation of the dopaminergic pathway in the brain reward system. Chronic exposure to nicotine activates neuroadaptation and associative learning with the nicotine-related stimulus through dopaminergic or cholinergic systems, which can lead to nicotine dependence or withdrawal. In sum, the neurobiological processes described above are deeply involved in the basis of nicotine dependence and underlie the frequent failure of attempts to quit smoking. In this review we discuss the neurobiological mechanisms of nicotine addiction focusing on the roles of the nicotinic acetylcholine receptor.
Abstract
Nicotine is the major substance that accounts for the addictive nature of smoking. Nicotine induces neurobiological and behavioral responses through diverse neurochemical mechanisms over the central nervous system. The brain reward system, particularly the dopaminergic pathway from the ventral tegmental area to nucleus accumbens, is central to understanding the behavioral reinforcement underlying substance addictions such as the addiction to nicotine. Nicotine acts as an agonist provoking activation or desensitization of nicotinic acetylcholine receptors in different brain areas including the brain reward system. Nicotine also indirectly influences the glutaminergic, GABAergic, noradrenergic, and serotonergic neurotransmission that lead ultimately to activation of the dopaminergic pathway in the brain reward system. Chronic exposure to nicotine activates neuroadaptation and associative learning with the nicotine-related stimulus through dopaminergic or cholinergic systems, which can lead to nicotine dependence or withdrawal. In sum, the neurobiological processes described above are deeply involved in the basis of nicotine dependence and underlie the frequent failure of attempts to quit smoking. In this review we discuss the neurobiological mechanisms of nicotine addiction focusing on the roles of the nicotinic acetylcholine receptor.
참고문헌 (50)
- Brust JCM, "Neurological aspects of substance abuse. 2 ed", pp.477~ (2004), Elsevier
- Tobacco or health, a global status report, "World Health Organization", World Health Organization, ~ (1997)
- Hughes JR, "Motivating and helping smokers to stop smoking", J Gen Intern Med, 18, pp.1053~1057 (2003)
- US Department of Health and Human Services, "The health consequencesof smoking: nicotine addiction" (1988), Office of Surgeon General US Department of Health and Human Services
- Benowitz NL, "Neurobiology of nicotine addiction: implications forsmoking cessation treatment", Am J Med, 121(4-1), pp.S3~S10 (2008)
- Giovino GA, "Epidemiology of tobacco use and dependence", Epidemiol Rev, 17, pp.48~65 (1995)
- Hughes JR, "Smoking cessation among self-quitters", Health Psychol, 11, pp.331~334 (1992)
- Rigotti NA, "Smoking cessation following admission to a coronary care unit", J Gen Intern Med, 6, pp.305~311 (1991)
- Himbury S, "Smoking habits after laryngectomy", Br Med J, 291, pp.514~515 (1985)
- Walker MS, "Smoking relapse during the first year after treatment for earlystage non-small-cell lung cancer", Cancer Epidemiol Biomarkers Prev, 15, pp.2370~2377 (2006)
- Stolerman IP, "The neurobiology of tobacco addiction", Trends Pharmacol Sci, 12, pp.467~473 (1991)
- Gotti C, "Heterogeneity and complexity of native brain nicotinic receptors", Biochem Pharmacol, 74, pp.1102~1111 (2007)
- Rose JE, "Multiple brain pathways and receptors underlying tobacco addiction", Biochem Pharmacol, 74, pp.1263~1270 (2007)
- Laviolette SR, "The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour", Nat Rev, 5, pp.55~65 (2004)
- Hays JT, "Efficacy and safety of varenicline for smoking cessation", Am J Med, 121(4), pp.S32~S42 (2008)
- Karam-Hage M, "Pharmacotherapy for tobacco cessation: nicotine agonists, antagonists, and partial agonists", Curr Oncol Rep, 9, pp.509~516 (2007)
- Cahill K, "Nicotine receptor partial agonists for smoking cessation", Cochrane database of syst Rev, pp.CD006103~ (2008)
- Robinson TE, "The neural basis of drug craving: an incentive-sensitization theory of addiction", Brain Res Rev, 18, pp.247~291 (1993)
- Fagen ZM, "Short- and long-term modulation of synaptic inputs to brain reward areas by nicotine", Ann N Y Acad Sci, 1003, pp.185~195 (2003)
- Omelchenko N, "Cholinergic axons in the rat ventral tegmental area synapse preferentially onto mesoaccumbens dopamine neurons", J Comp Neurol, 494, pp.863~875 (2006)
- Fiorillo CD, "Cholinergic inhibition of ventral midbrain dopamine neurons", J Neurosci, 20, pp.7855~7860 (2000)
- Garzon M, "Cholinergic axon terminals in the ventral tegmental area target a subpopulation of neurons expressing low levels of the dopamine transporter", J Comp Neurol, 410, pp.197~210 (1999)
- Tzschentke TM, "Pharmacology and behavioral pharmacology of the mesocortical dopamine system", Prog Neurobiol, 63, pp.241~320 (2001)
- Schechter MD, "Further evidence for the mechanisms that may mediate nicotine discrimination", Pharmacol Biochem Behav, 41, pp.807~812 (1992)
- Stolerman IP, "Discrimination and self-administration of nicotine by inbred strains of mice", Psychopharmacology, 141, pp.297~306 (1999)
- Takada K, "Discriminative stimulus effects of intravenous nicotine in squirrel monkeys", Pharmacol Biochem Behav, 30, pp.243~247 (1988)
- Schechter MD, "Effect of mecamylamine on discrimination between nicotine-and arecoline-produced cues", Eur J Pharmacol, 17, pp.179~182 (1972)
- Karan LD, "The Pharmacology of nicotine and tobacco. in: Principles of addiction medicine, 3rd ed", pp.225~248 (2003), American Society of Addiction Medicine
- Henningfield JE, "Cigarette smokers selfadminister intravenous nicotine", Pharmacol Biochem Behav, 19, pp.887~890 (1983)
- Rose JE, "Acute effects of nicotine and mecamylamine on tobacco withdrawal symptoms, cigarette reward and ad lib smoking", Pharmacol Biochem Behav, 68, pp.187~197 (2001)
- Dar R, "Do smokers self-administer pure nicotine? A review of the evidence", Psychopharmacology, 173, pp.18~26 (2004)
- Laviolette SR, "The motivational valence of nicotine in the rat ventral tegmental area is switched from rewarding to aversive following blockade of the alpha7-subunit-containing nicotinic acetylcholine receptor", Psychopharmacology, 166, pp.306~313 (2003)
- Glautier S, "Measures and models of nicotine dependence: positive reinforcement", Addiction, 99(1), pp.30~50 (2004)
- Rigotti NA, "Clinical practice. Treatment of tobacco use and dependence", N Engl J Med, 346, pp.506~512 (2002)
- Kalivas PW, "The neural basis of addiction: a pathology of motivation and choice", Am J Psychiatry, 162, pp.1403~1413 (2005)
- Watkins SS, "Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal", Nicotine Tob Res, 2, pp.19~37 (2000)
- Pomerleau CS, "Euphoriant effects of nicotine in smokers", Psychopharmacology, 108, pp.460~465 (1992)
- Benowitz NL, "Pharmacology of nicotine: addiction and therapeutics", Annu Rev Pharmacol Toxicol, 36, pp.597~613 (1996)
- Stolerman IP, "The scientific case that nicotine is addictive", Psychopharmacology, 117, pp.2~10 (1995)
- Hughes JR, "Symptoms of tobacco withdrawal. A replication and extension", Arch Gen Psychiatry, 48, pp.52~59 (1991)
- Markou A, "Neurobiological similarities in depression and drug dependence: a self-medication hypothesis", Neuropsychopharmacology, 18, pp.135~174 (1998)
- Fagerström KO, "Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment", Addict Behav, 3, pp.235~241 (1978)
- Heatherton TF, "The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire", Br J Addict, 86, pp.1119~1127 (1991)
- 안희경, "한국어판 니코틴 의존도 설문 도구(Fagerstrom Tolerance Questionnaire, FTQ and Fagerstrom Test for Nicotine Dependence, FTND)의 신뢰도 및 타당도", Korean Journal of Family Medicine, 23(8), pp.999~1008 (2002), 대한가정의학회
- American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. 4 ed" (1994), American Psychiatric Press
- Hughes JR, "Prevalence of DSM", ICD-defined nicotine dependence, 2006, pp.85, 91~102
- Ministry of Health and Welfare and Family Affair, "The Epidemiological Survey of Psychiatric Illnesses in Korea" (2006), Ministry for Health and Welfare, Seoul University
- Kandel D, "Prevalence and demographic correlates of symptoms of last year dependence on alcohol, nicotine, marijuana and cocaine in the U.S. population", Drug Alcohol Depend, 44, pp.11~29 (1997)
- Shiffman S, "The nicotine dependence syndrome scale: a multidimensional measure of nicotine dependence", Nicotine Tob Res, 6, pp.327~348 (2004)
- 박재우, "한국판 니코틴 의존 증후군 척도의 표준화와 금연 예측 인자로서의 유용성", 신경정신의학, 46(1), pp.58~64 (2007), 대한신경정신의학회